

Amendments to the Claims

1-141. (Canceled)

142. (Currently Amended) ~~The~~ An isolated antibody ~~of claim 128 further~~ comprising a VH CDR1 having the amino acid sequence of SEQ ID NO:26, a VH CDR2 having the amino acid sequence of SEQ ID NO:2, a VH CDR3 having the amino acid sequence of SEQ ID NO:3, a VL CDR1 having the amino acid sequence of SEQ ID NO:62, a VL CDR2 having the amino acid sequence of SEQ ID NO:65, and a VL CDR3 having the amino acid sequence of SEQ ID NO:20.

143-153. (Canceled)

154. (Previously Presented) An isolated antibody which is encoded by the vector deposited as ATCC deposit No. PTA-5913.

155. (Currently Amended) The isolated antibody of claim ~~128, 135, 142, 143, 144, 145~~ or 154, wherein the antibody is conjugated to a therapeutic or drug moiety.

156. (Currently Amended) The isolated antibody of claim ~~128, 135, 142, 143, 144, 145~~ or 154, wherein the antibody is conjugated to a detectable substance.

157. (Currently Amended) A pharmaceutical composition comprising the antibody of claim ~~128, 135, 142, 143, 144, 145~~ or 154 and a pharmaceutically acceptable carrier or excipient.

158. (Previously Presented) The pharmaceutical composition of claim 157 formulated for pulmonary, intranasal, oral, subcutaneous, intradermal or parental administration.

159. (Previously Presented) The pharmaceutical composition of claim 157 formulated for sustained release formulation.

160. (Currently Amended) A lyophilized formulation comprising the antibody of claim ~~128,~~
~~135,~~ 142, ~~143,~~ ~~144,~~ ~~145~~ or 154.

161. (Currently Amended) A liquid formulation comprising the antibody of claim ~~128,~~ ~~135,~~
~~142,~~ ~~143,~~ ~~144,~~ ~~145~~ or 154.

162. (Currently Amended) A kit comprising the antibody of claim ~~128,~~ ~~135,~~ 142, ~~143,~~ ~~144,~~
~~145~~ or 154, in one or more containers, and instructions for use.

163-168. (Canceled)